<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!-- Created with Liquid XML Studio - FREE Community Edition 7.1.6.1440 (http://www.liquid-technologies.com) -->
<ns2:studies xmlns:ns2="http://webservice.caaers.cabig.nci.nih.gov">
	<ns2:study>
		<shortTitle>Phase I Trial of the Combination of GDC-0449 and Erlotinib</shortTitle>
		<longTitle>Phase I Trial of the Combination of GDC-0449 and Erlotinib</longTitle>
		<description>Phase I Trial of the Combination of GDC-0449 and Erlotinib</description>
		<phaseCode>Phase I Trial</phaseCode>
		<status>Active - Trial is open to accrual</status>
		<multiInstitutionIndicator>true</multiInstitutionIndicator>
		<adeersReporting>true</adeersReporting>
		<otherMeddra>MedDRA v9</otherMeddra>
		<ns2:aeTerminology>
			<ns2:ctcVersion>
				<name>3</name>
			</ns2:ctcVersion>
		</ns2:aeTerminology>
		<ns2:diseaseTerminology>
			<diseaseCodeTerm>CTEP</diseaseCodeTerm>
		</ns2:diseaseTerminology>
		<drugAdministrationTherapyType>true</drugAdministrationTherapyType>
		<deviceTherapyType>false</deviceTherapyType>
		<radiationTherapyType>false</radiationTherapyType>
		<surgeryTherapyType>false</surgeryTherapyType>
		<behavioralTherapyType>false</behavioralTherapyType>
		<biologicalTherapyType>false</biologicalTherapyType>
		<geneticTherapyType>false</geneticTherapyType>
		<dietarySupplementTherapyType>false</dietarySupplementTherapyType>
		<otherTherapyType>false</otherTherapyType>
		<reportTypeCaaersXML>true</reportTypeCaaersXML>
		<reportTypeAdeersPDF>true</reportTypeAdeersPDF>
		<reportTypeMedwatchPDF>true</reportTypeMedwatchPDF>
		<reportTypeDCPSAEForm>false</reportTypeDCPSAEForm>
		<reportTypeCIOMSForm>false</reportTypeCIOMSForm>
		<reportTypeCIOMSAEForm>false</reportTypeCIOMSAEForm>
		<fundingSponsor>
			<organizationAssignedIdentifier>
				<value>8231</value>
			</organizationAssignedIdentifier>
			<ns2:studyFundingSponsor>
				<ns2:organization>
					<name>Cancer Therapy Evaluation Program</name>
					<nciInstituteCode>CTEP</nciInstituteCode>
				</ns2:organization>
			</ns2:studyFundingSponsor>
		</fundingSponsor>
		<coordinatingCenter>
			<organizationAssignedIdentifier>
				<value>MC0811</value>
			</organizationAssignedIdentifier>
			<ns2:studyCoordinatingCenter>
				<ns2:organization>
					<name>Kenyatta National Hospital</name>
					<nciInstituteCode>100001</nciInstituteCode>
				</ns2:organization>
			</ns2:studyCoordinatingCenter>
		</coordinatingCenter>
		<studyOrganizations>
			<ns2:studySite>
				<ns2:organization>
					<name>Karnataka Cancer Therapy and Research Institute</name>
					<nciInstituteCode>37007</nciInstituteCode>
				</ns2:organization>
				<studyInvestigators>
					<ns2:studyInvestigator>
						<roleCode>SI</roleCode>
						<startDate>2010-01-01</startDate>
						<ns2:siteInvestigator>
							<ns2:investigator>
								<firstName>John</firstName>
								<lastName>inv1</lastName>
								<nciIdentifier>inv-5876-v1</nciIdentifier>
							</ns2:investigator>
						</ns2:siteInvestigator>
					</ns2:studyInvestigator>
				</studyInvestigators>
				<studyPersonnels>
					<ns2:studyPersonnel>
						<roleCode>caaers_participant_cd</roleCode>
						<startDate>2009-08-31</startDate>
						<endDate>2011-02-01</endDate>
						<ns2:researchStaff>
							<firstName>robert</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>rs-5876-v1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_ae_cd</roleCode>
						<startDate>2009-08-31</startDate>
						<ns2:researchStaff>
							<firstName>robert</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>rs-5876-v1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
				</studyPersonnels>
			</ns2:studySite>
		</studyOrganizations>
		<identifiers />
		<treatmentAssignments>
			<ns2:treatmentAssignment>
				<code>A-1</code>
				<description>Cycle = 28 days:
GDC-0449:  150 mg PO QD
Erlotinib:  25 mg PO QD</description>
			</ns2:treatmentAssignment>
			<ns2:treatmentAssignment>
				<code>A1</code>
				<description>Cycle = 28 days:
GDC-0449:  150 mg PO QD
Erlotinib:  50 mg PO QD</description>
			</ns2:treatmentAssignment>
			<ns2:treatmentAssignment>
				<code>A2</code>
				<description>Cycle = 28 days:
GDC-0449:  150 mg PO QD
Erlotinib:  75 mg PO QD</description>
			</ns2:treatmentAssignment>
			<ns2:treatmentAssignment>
				<code>A3</code>
				<description>Cycle = 28 days:
GDC-0449:  150 mg PO QD
Erlotinib: 100 mg PO QD</description>
			</ns2:treatmentAssignment>
			<ns2:treatmentAssignment>
				<code>A4</code>
				<description>Cycle = 28 days:
GDC-0449:  150 mg PO QD
Erlotinib:  150 mg PO QD</description>
			</ns2:treatmentAssignment>
			<ns2:treatmentAssignment>
				<code>FDG</code>
				<description>FDG:   0.14-0.21 mCi/kg IVB 
Note:   Dose at higher end of range is recommended, with reduction in per kg dose for heavier patients</description>
			</ns2:treatmentAssignment>
		</treatmentAssignments>
		<studyAgents>
			<ns2:studyAgent>
				<ns2:agent>
					<name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose (18F-FDG)</name>
				</ns2:agent>
				<indType>NA_COMMERCIAL</indType>
			</ns2:studyAgent>
			<ns2:studyAgent>
				<ns2:agent>
					<name>GDC-0449</name>
				</ns2:agent>
				<indType>CTEP_IND</indType>
				<partOfLeadIND>true</partOfLeadIND>
				<studyAgentINDAssociations>
					<ns2:studyAgentINDAssociation>
						<ns2:investigationalNewDrug>
							<indNumber>-111</indNumber>
						</ns2:investigationalNewDrug>
					</ns2:studyAgentINDAssociation>
				</studyAgentINDAssociations>
			</ns2:studyAgent>
			<ns2:studyAgent>
				<ns2:agent>
					<name>OSI-774 (erlotinib; Tarceva)</name>
				</ns2:agent>
				<indType>CTEP_IND</indType>
				<partOfLeadIND>false</partOfLeadIND>
				<studyAgentINDAssociations>
					<ns2:studyAgentINDAssociation>
						<ns2:investigationalNewDrug>
							<indNumber>-111</indNumber>
						</ns2:investigationalNewDrug>
					</ns2:studyAgentINDAssociation>
				</studyAgentINDAssociations>
			</ns2:studyAgent>
		</studyAgents>
		<ctepStudyDiseases>
			<ns2:ctepStudyDisease>
				<ns2:diseaseTerm>
					<term>Adenocarcinoma - pancreas</term>
				</ns2:diseaseTerm>
				<leadDisease>false</leadDisease>
			</ns2:ctepStudyDisease>
			<ns2:ctepStudyDisease>
				<ns2:diseaseTerm>
					<term>Solid tumor, NOS</term>
				</ns2:diseaseTerm>
				<leadDisease>true</leadDisease>
			</ns2:ctepStudyDisease>
			<ns2:ctepStudyDisease>
				<ns2:diseaseTerm>
					<term>Hematopoietic malignancy, NOS</term>
				</ns2:diseaseTerm>
				<leadDisease>false</leadDisease>
			</ns2:ctepStudyDisease>
		</ctepStudyDiseases>
		<evaluationPeriods>
			<ns2:evaluationPeriod>
				<name>Baseline</name>
				<epochOrder>0</epochOrder>
			</ns2:evaluationPeriod>
			<ns2:evaluationPeriod>
				<name>Treatment</name>
				<epochOrder>1</epochOrder>
			</ns2:evaluationPeriod>
			<ns2:evaluationPeriod>
				<name>Post-treatment</name>
				<epochOrder>2</epochOrder>
			</ns2:evaluationPeriod>
		</evaluationPeriods>
	</ns2:study>
</ns2:studies>